FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm Larvae
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each with Padcev® , as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for WINREVAIR®
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir in Treatment-Naïve Adults with HIV-1 Infection
European Commission Approves Subcutaneous Administration of KEYTRUDA® for All Adult Indications Approved in the European Union
Merck's WINREVAIR Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial
Tartisan Nickel Corp. Announces Rodren Drilling has Commenced Drilling at the Kenbridge Nickel Copper Cobalt Project, Sioux Narrows, Northwestern, Ontario
Momentum Builds, Upside Appears as Mining Explorers Transition Toward Production, Unlock Major Hidden Value
